If you are looking for an AI stock that is more promising than PLX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025. The Dow Jones closed lower by ...

Protalix BioTherapeutics, Inc.’s PLX share price has surged by 8.71%, which has investors questioning if this is right time to sell.

$PLX ($PLX) is expected to release its quarterly earnings data on Monday, March 17th before market open, per Finnhub. Analysts are expecting revenue of $18,940,530 ...

In a report released on April 17, Julien Richer from Kepler Capital maintained a Buy rating on PLUXEE N.V. (PLX – Research Report), with a ...

but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in PLX over the next 72 hours. I wrote this article myself ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Protalix Biotherapeutics (PLX) has gained investor’s attention, and reported a record revenue increase in its fiscal year 2024, primarily due to sales to Chiesi, Pfizer (PFE), and Brazil.

Assess today's live PLX Technology Inc (PLXT) share price, performance and insights using our live NASDAQ: PLXT stock exchange data. Analyse the historical data and PLX Technology Inc share price ...

ByInvesting.com • Aug 14, 2024 PLX stock touches 52-week low at $0.97 amid market challenges Protalix Biotherapeutics Inc. (NYSE:PLX) stock has reached a 52-week low, trading at $0.97 ...